Biovest to Present BiovaxID™ Cancer Vaccine Update at Lymphoma Coalition Patient Advocacy Event prior to ASH Meeting

TAMPA, Fla. & MINNEAPOLIS--()--Biovest International, Inc. (OTCQB: “BVTI”), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: “ABPI”), today announced that Biovest will present at the Lymphoma Coalition’s annual patient advocacy event leading up to the American Society of Hematology (ASH) Annual Meeting in Atlanta, Dec. 8-11. Biovest will provide an update on BiovaxID™, its late-stage, personalized cancer vaccine for the treatment of non-Hodgkin’s lymphoma, which has been featured in a series of recent web-based articles by lymphoma patient advocates reporting on the urgent, unmet need for additional consolidation therapeutic options for lymphoma patients concerned with safety and side-effects.

BiovaxID Presentation Details:

Event: Lymphoma Coalition Presentation & Reception Evening

Day/Time: Thursday, December 6th at 4:30 pm EST

Place: Marriott Perimeter Centre, 246 Perimeter Centre Parkway NE, Atlanta, Georgia

For More Information: www.lymphomacoalition.org

To review articles by lymphoma patient advocates reporting on BiovaxID and the unmet need for additional consolidation therapeutic options, please visit the following publication links:

To request a meeting with Biovest at this Lymphoma Coalition event or at ASH, please contact Douglas Calder at 813-507-2558 or dwcalder@biovest.com.

About Biovest International, Inc.

Biovest International, Inc. develops active immunotherapies (cancer vaccines) which treat and diminish the aggressiveness of B-cell non-Hodgkin’s lymphoma, a cancer of the immune system. The Company’s lead personalized cancer vaccine product candidate, BiovaxID™, has been evaluated in three clinical trials conducted in collaboration with the U.S. National Cancer Institute (NCI) demonstrating that BiovaxID increases the duration of cancer remission following chemotherapy and induces immune responses which correlate highly with long-term survival. Biovest is currently in the process of pursuing European and Canadian marketing approvals for BiovaxID.

Headquartered in Tampa, Florida with its bio-manufacturing facility based in Minneapolis, Minnesota, Biovest is publicly-traded on the OTCQB™ Market with the stock-ticker symbol “BVTI”, and is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTCQB: “ABPI”).

For further information, please visit: http://www.biovest.com

Forward-Looking Statements:

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements.” Such statements include, but are not limited to, statements about Biovest and its product candidate, BiovaxID™ and any other statements relating to products, product candidates, product development programs, the FDA, the EMA, Health Canada or clinical study process including the commencement, process, or completion of clinical trials or the regulatory process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions, and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions. In particular (and without limitation), statements regarding the timing of anticipated filing of a Marketing Authorization Application for BiovaxID with the EMA or a New Drug Submission for BiovaxID with Health Canada, pre-filing meetings with the FDA or other jurisdictions and/or commercial plans reflect current expectations but are subject to inherent risks of delay in compilation and finalization of all components of the licensing application. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Biovest to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Biovest undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. The product names used in this statement are for identification purposes only. All trademarks and registered trademarks are the property of their respective owners.

Contacts

Biovest International, Inc.
Douglas Calder, 813-864-2558
Vice President, Strategic Planning & Capital Markets
Email: dwcalder@biovest.com

Release Summary

Biovest will present on its cancer vaccine, BiovaxID, at the Lymphoma Coalition Event leading up to the ASH Conference. Patients have initiated a petition drive calling for the vaccine's approval.

Sharing

Contacts

Biovest International, Inc.
Douglas Calder, 813-864-2558
Vice President, Strategic Planning & Capital Markets
Email: dwcalder@biovest.com